Gathering the record
Relay is organizing the evidence and source boundaries.
Endogenous pyridine-dinucleotide coenzyme / redox cofactor
NAD+ is a coenzyme every cell uses for energy metabolism, redox balance, DNA repair, and signaling. People research it for energy, aging, recovery, cognition, and metabolic health, but most human 'NAD-boosting' data come from NR or NMN—not NAD+ itself. Direct IV evidence is limited to one disease-specific randomized trial and very small metabolism and tolerability studies.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
NAD+ is a helper molecule used by every cell for energy chemistry, redox balance, DNA repair, and signaling. Direct NAD+ is different from precursor molecules such as NR or NMN.
Because NAD-related biology changes with metabolism and age, researchers study whether direct administration or precursor supplementation can affect disease or function. Evidence must stay attached to the exact molecule and route.
A 180-person randomized heart-failure study reported a short-term heart-pumping signal after intravenous NAD+, but secondary clinical measures were not statistically significant. Very small infusion studies describe metabolism and tolerability, including gastrointestinal symptoms, faster heart rate, and chest pressure. Most broader human evidence concerns NR or NMN instead.
Durable disease benefit, anti-aging, energy, cognition, recovery, addiction, weight, and longevity effects from direct NAD+ remain unestablished. Formulation-specific short- and long-term safety also remains uncertain.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A single-center randomized trial investigated intravenous NAD+ alongside guideline-directed care in adults with heart failure caused by ischemic cardiomyopathy.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
The direct NAD+ record is small; most broader literature belongs to NR or NMN.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
One controlled disease-specific signal has not established general wellness outcomes.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The trial was disease-specific, single-center, short, and too small to establish effects on major clinical events. It does not establish wellness, anti-aging, cognition, recovery, addiction, weight, or longevity benefits. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
A 180-person randomized placebo-controlled trial in ischemic-cardiomyopathy heart failure found a short-term LVEF signal; it was single-center, disease-specific, and not a wellness or anti-aging trial
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether direct NAD+ produces meaningful, durable benefits outside that narrow heart-failure setting and what formulation-specific short- and long-term safety looks like
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
They are related members of the same metabolic network, but they enter the body and cells differently and have different human studies, routes, side effects, and regulatory contexts.
Cells use the NAD+/NADH pair to move electrons during energy metabolism. NAD+ is also consumed by sirtuins, PARPs, CD38, and related enzymes.
A 2026 systematic review found no eligible IV or IM NAD+ outcomes trial for anti-aging or wellness. The broader human literature mostly studied oral NR or NMN.
Among 180 adults with heart failure from ischemic cardiomyopathy, seven days of hospital-administered IV NAD+ improved average LVEF more than placebo at 1 month.
In an 11-person pilot, measured plasma NAD+ and metabolites did not rise during the first 2 hours, while urinary NAD+ and methyl-nicotinamide increased later.
In a six-person NAD+ record review, clients reported gastrointestinal symptoms, faster heart rate, and chest pressure that resolved after the infusion; the average infusion took about 97 minutes.
FDA has received reports of severe chills, shaking, vomiting, and fatigue. In a 2026 warning letter, an unopened vial from a reaction-linked lot contained very high bacterial endotoxin levels.
There is no approved U.S. NAD+ product label that establishes a standard indication, injectable formulation, dose, route, manufacturing specification, or storage procedure.
Published studies used very different hospital or commercial IV regimens for different questions. Those protocols describe the studies; they are not general instructions.
These are common reasons people discuss NAD+, but direct clinical outcomes evidence is missing or insufficient. Precursor, NADH, animal, and mechanistic studies do not fill that gap.
Mechanisms
Oxidized nicotinamide adenine dinucleotide is the electron-accepting member of the NAD+/NADH redox pair and a substrate for sirtuins, PARPs, CD38, and related enzymes. Direct human research includes an 180-person single-center randomized trial in ischemic-cardiomyopathy heart failure, an 11-person IV metabolic-disposition pilot, and a 14-person commercial-record comparison containing six NAD+ recipients. The heart-failure trial reported a larger short-term LVEF improvement but nonsignificant trends for clinical events and functional measures. The IV pilots show rapid metabolism and potentially substantial infusion symptoms, not wellness effectiveness. A 2026 systematic review found no eligible IV or IM NAD+ outcomes trial for anti-aging or wellness. FDA has also documented endotoxin-related injectable reactions and a 503B compounding-eligibility problem.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Single-center, prospective, randomized, placebo-controlled trial alongside guideline-directed heart-failure therapy
180 adults with heart failure caused by ischemic cardiomyopathy, LVEF at or below 45%, and NYHA class II or III
The NAD+ group had a larger average LVEF improvement than placebo at 1 month. Secondary biomarker, hospitalization, event, and functional-class differences were trends that did not reach conventional statistical significance.
Study administration: Intravenous NAD+ 10 mg once daily for 7 days versus matched glucose or saline placebo; this was a study-specific hospital protocol
Limitations: This was one single-center disease-specific trial, not a wellness study. It was too small for clinical events, follow-up was short, SGLT2-inhibitor use was low, and the manufacturer supplied study drug and funding. The result does not establish longevity, energy, cognition, addiction recovery, or a general IV protocol.
PRISMA-guided systematic review of human and rodent NAD-related intervention studies published from 2010 through October 2025
113 studies: 33 human intervention studies and 80 rodent studies
NR and NMN usually raised NAD-related biomarkers, but functional and health outcomes were mixed and often null or endpoint-specific. The review found no eligible outcomes trial of IV or IM NAD+ itself for anti-aging or wellness.
Study administration: NAD-related compounds across routes; most human evidence involved oral NR or NMN rather than direct NAD+
Limitations: The review combines different molecules, routes, populations, and endpoints. Results from NR, NMN, niacin, nicotinamide, or NADH cannot be assigned to direct NAD+.
Retrospective electronic-record review from a commercial wellness setting; nonrandomized NAD+ versus NR groups
14 commercial clients: 6 received IV NAD+ and 8 received IV nicotinamide riboside
The six NAD+ clients reported moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusions; symptoms resolved after infusion. NAD+ infusions averaged about 97 minutes versus 37 minutes for NR. Exploratory laboratory changes were variable and stayed within normal ranges.
Study administration: 500 mg IV NAD+ or 500 mg IV NR on four consecutive days; participants could slow the flow rate for tolerability
Limitations: The sample was tiny, retrospective, commercially selected, nonrandomized, and company-employed investigators analyzed company records. It cannot establish effectiveness, comparative superiority, rare-event safety, or durability.
Small randomized metabolic-disposition pilot with intensive plasma and urine sampling
11 men aged 30 to 55: 8 received NAD+ and 3 received saline
Plasma NAD+ and measured metabolites did not rise during the first 2 hours. By 6 hours, urinary NAD+ and methyl-nicotinamide increased, consistent with rapid removal and metabolism of infused NAD+.
Study administration: The test group received 750 mg IV NAD+ over 6 hours; this was a study regimen derived from commercial-clinic practice, not an approved protocol
Limitations: Only eight participants received NAD+, the control group had three people, all were men, and the study measured disposition rather than fatigue, cognition, longevity, recovery, or other clinical benefit.
Safety snapshot
Injectable NAD+ has a documented sterile-product and endotoxin risk.
Other human evidenceThese events demonstrate product-quality risk and do not establish the intrinsic adverse-event rate of correctly manufactured pure NAD+.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Injectable NAD+ has a documented sterile-product and endotoxin risk.
Other human evidenceThese events demonstrate product-quality risk and do not establish the intrinsic adverse-event rate of correctly manufactured pure NAD+.
Open sourceThe current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-23 · PMID 42489969 · DOI 10.1007/s11033-026-12351-3
2026-02-06 · PMID 41655607 · DOI 10.1016/j.arr.2026.103057
2026-02-02 · PMID 41704678 · DOI 10.3389/fragi.2026.1652582
2026-01-20
2025-09-15 · PMID 40954388 · ChiCTR2200059169 · DOI 10.1007/s40256-025-00764-7
2019-09-12 · PMID 31572171 · DOI 10.3389/fnagi.2019.00257